[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Zhang et al., 2015 - Google Patents

Current status of immunomodulatory therapy in chronic hepatitis B, fifty years after discovery of the virus: Search for the “magic bullet” to kill cccDNA

Zhang et al., 2015

Document ID
13842267742335280668
Author
Zhang E
Kosinska A
Lu M
Yan H
Roggendorf M
Publication year
Publication venue
Antiviral research

External Links

Snippet

Chronic hepatitis B (CHB) is currently treated with IFN-α and nucleos (t) ide analogues, which have many clinical benefits, but there is no ultimate cure. The major problem consists in the persistence of cccDNA in infected hepatocytes. Because no antiviral drug has been …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse Transcribing DNA Viruses
    • C12N2730/00011—Reverse Transcribing DNA Viruses
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse Transcribing DNA Viruses
    • C12N2730/00011—Reverse Transcribing DNA Viruses
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Similar Documents

Publication Publication Date Title
Zhang et al. Current status of immunomodulatory therapy in chronic hepatitis B, fifty years after discovery of the virus: Search for the “magic bullet” to kill cccDNA
Kosinska et al. Therapeutic vaccination for chronic hepatitis B
Yang et al. Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study
Kose et al. Seroprevalence of hepatitis B and C among oncology patients in Turkey
Cova Present and future DNA vaccines for chronic hepatitis B treatment
Iannacone et al. Immunological insights in the treatment of chronic hepatitis B
Laupèze et al. A role for immune modulation in achieving functional cure for chronic hepatitis B among current changes in the landscape of new treatments
Wang et al. Recent advances in understanding T cell activation and exhaustion during HBV infection
Zhang et al. Woodchuck hepatitis virus core antigen-based DNA and protein vaccines induce qualitatively different immune responses that affect T cell recall responses and antiviral effects
Ghasemi et al. Current progress in the development of therapeutic vaccines for chronic hepatitis B virus infection
Shen et al. Prior transient exposure to interleukin-21 delivered by recombinant adeno-associated virus vector protects mice from hepatitis B virus persistence
Khawaja et al. In vivo electroporation improves therapeutic potency of a DNA vaccine targeting hepadnaviral proteins
Wen et al. Vaccine therapies for chronic hepatitis B: can we go further?
Aguilar et al. Immunotherapy for chronic hepatitis B using HBsAg-based vaccine formulations: from preventive commercial vaccines to therapeutic approach julio cesar aguilar
Kang et al. The unique antibody suppresses HBV viremia and reduces hepatocarcinogenesis in HBV-transgenic mice
Chuai et al. HBV antigen and DNA loss from mouse serum is associated with novel vaccine-induced HBV surface antigen-specific cell-mediated immunity and cytokine production
Li et al. Chronic and occult hepatitis B virus infections in the vaccinated Chinese population
Kim et al. Lenvervimab, a monoclonal antibody against HBsAg, can induce sustained HBsAg loss in a chronic hepatitis B mouse model
Cova Progress in DNA vaccination against HBV infection
Akbar et al. Current trends in hepatitis B vaccination
Smith Hepatitis A hepatitis B vaccine
Pogorelskaya et al. Prospects of the use" Stimforte" in chronic hepatitis B
Okagawa Reactivation of hepatitis B virus: case report
Poyraz et al. New developments in the era of viral hepatitis vaccines
Akbar et al. Non-antigen-specific and antigen-specific immune therapies for chronic hepatitis B: Evidences from laboratory benches and patient's bedsides